Literature DB >> 31062253

Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis.

Afsaneh Enteshari-Moghaddam1, Ahad Azami1, Khatereh Isazadehfar2, Hamed Mohebbi3,4, Afshin Habibzadeh1, Parinaz Jahanpanah5.   

Abstract

INTRODUCTION: Knee osteoarthritis (OA) is a common form of arthritis in elders which can lead to reduced daily activity and quality of life. It is important to administer a proper treatment with high efficacy and low side effects. In this study, we evaluated the efficacy of duloxetine and gabapentin in patients with moderate to severe knee OA.
METHOD: In this randomized clinical trial, 150 patients with moderate to severe knee OA were randomly allocated to receive duloxetine 30 mg (n = 50), gabapentin 300 mg (n = 50), or acetaminophen 1000 mg (n = 50) all twice a day for 12 weeks. Pain severity using visual analogue scale (VAS) and functional status using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were measured before, 2 weeks, 1 month, and 3 months after intervention.
RESULTS: WOMAC total and its subscale score were significantly lower in duloxetine compared to gabapentin in 2 weeks and 1 months after intervention, with no significant difference at the end of the third month. Both gabapentin and duloxetine groups had significantly more reduction in pain VAS and WOMAC and its subscales compared to acetaminophen group, with no significant difference between groups.
CONCLUSIONS: Both gabapentin and duloxetine have similar and acceptable effects in pain reduction and improvement of functional status in patients with knee OA at the end of the third month's treatment. Duloxetine effects begin from the first weeks, while gabapentin effects begin gradually with the best at the end of the third month. KEY POINTS: • Medical treatment is used for releiving pain in knee osteoarthritis. • Gabapentin and duloxetine are both effective in reducing pain in knee osteoarthritis.

Entities:  

Keywords:  Duloxetine; Gabapentin; Knee osteoarthritis; Pain

Mesh:

Substances:

Year:  2019        PMID: 31062253     DOI: 10.1007/s10067-019-04573-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.

Authors:  Héctor Arreola Ornelas; Alfonso Rosado Buzzo; Lourdes García; Javier Dorantes Aguilar; Iris Contreras Hernández; Joaquín F Mould Quevedo
Journal:  Reumatol Clin       Date:  2012-03-03

Review 2.  Gabapentin for chronic neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; Rae F Bell; Andrew Sc Rice; Thomas Rudolf Tölle; Tudor Phillips; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-09

3.  OARSI guidelines for the non-surgical management of knee osteoarthritis.

Authors:  T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood
Journal:  Osteoarthritis Cartilage       Date:  2014-01-24       Impact factor: 6.576

4.  Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.

Authors:  Amy S Chappell; Melissa J Ossanna; Hong Liu-Seifert; Smriti Iyengar; Vladimir Skljarevski; Linda Chunhong Li; Robert M Bennett; Harry Collins
Journal:  Pain       Date:  2009-07-21       Impact factor: 6.961

Review 5.  Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use.

Authors:  Elena P Calandre; Fernando Rico-Villademoros; Mahmoud Slim
Journal:  Expert Rev Neurother       Date:  2016-07-07       Impact factor: 4.618

6.  A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.

Authors:  Lesley M Arnold; Yili Lu; Leslie J Crofford; Madelaine Wohlreich; Michael J Detke; Smriti Iyengar; David J Goldstein
Journal:  Arthritis Rheum       Date:  2004-09

7.  Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Authors:  Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold
Journal:  Pain       Date:  2008-04-18       Impact factor: 6.961

8.  Thrombospondin-4 divergently regulates voltage-gated Ca2+ channel subtypes in sensory neurons after nerve injury.

Authors:  Bin Pan; Yuan Guo; Hsiang-En Wu; John Park; Van Nancy Trinh; Z David Luo; Quinn H Hogan
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

Review 9.  Knee osteoarthritis: pathophysiology and current treatment modalities.

Authors:  Juan C Mora; Rene Przkora; Yenisel Cruz-Almeida
Journal:  J Pain Res       Date:  2018-10-05       Impact factor: 3.133

10.  Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care.

Authors:  Jeffrey Scott Andrews; Ning Wu; Shih-Yin Chen; Xia Yu; Xiaomei Peng; Diego Novick
Journal:  J Pain Res       Date:  2013-11-26       Impact factor: 3.133

View more
  8 in total

1.  Comment on "Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis".

Authors:  Sinan Kardeş
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

2.  Pharmacological use of gamma-aminobutyric acid derivatives in osteoarthritis pain management: a systematic review.

Authors:  Ze Du; Hanxiao Chen; Yongrui Cai; Zongke Zhou
Journal:  BMC Rheumatol       Date:  2022-05-11

3.  The Central Aspects of Pain in the Knee (CAP-Knee) questionnaire; a mixed-methods study of a self-report instrument for assessing central mechanisms in people with knee pain.

Authors:  K Akin-Akinyosoye; R J E James; D F McWilliams; B Millar; R das Nair; E Ferguson; D A Walsh
Journal:  Osteoarthritis Cartilage       Date:  2021-02-20       Impact factor: 6.576

Review 4.  Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.

Authors:  Jeffrey N Katz; Kaetlyn R Arant; Richard F Loeser
Journal:  JAMA       Date:  2021-02-09       Impact factor: 56.272

5.  Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States.

Authors:  Jamie L Huizinga; Elizabeth E Stanley; James K Sullivan; Shuang Song; David J Hunter; A David Paltiel; Tuhina Neogi; Robert R Edwards; Jeffrey N Katz; Elena Losina
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-05-10       Impact factor: 5.178

6.  Association between serum Vitamin D deficiency and Knee Osteoarthritis.

Authors:  Hasan Anari; Afsaneh Enteshari-Moghaddam; Yeghaneh Abdolzadeh
Journal:  Mediterr J Rheumatol       Date:  2020-03-31

7.  Duloxetine combined with intra-articular injection versus intra-articular injection alone for pain relief in knee osteoarthritis: a study protocol for a randomised controlled trial.

Authors:  Duo Yi Li; Rong Han; Zhi Gang Zhao; Fang Luo
Journal:  BMJ Open       Date:  2020-10-27       Impact factor: 2.692

8.  Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.

Authors:  J K Sullivan; J Huizinga; R R Edwards; D J Hunter; T Neogi; E Yelin; J N Katz; E Losina
Journal:  Osteoarthritis Cartilage       Date:  2020-11-07       Impact factor: 6.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.